A gemcitabine prodrug for selective treatment of pancreatic ductal adenocarcinoma (ChemMedChem, 2019, in press)

A gemcitabine prodrug for selective treatment of pancreatic ductal adenocarcinoma (ChemMedChem, 2019, in press)
In the collaboration with the Graduate School of Pharmaceutical Sciences, Osaka University (Prof. Satoshi Obika), Matsushita, et al. developed a  gemcitabine prodrug. Given that the major concern in the use of anticancer chemotherapeutic drugs is host toxicity, this study will contribute to improve the treatment of pancreatic ductal adenocarcinoma.

前へ ＜

＞ 次へ

記事一覧に戻る